MBX Biosciences
Clinical trials sponsored by MBX Biosciences, explained in plain language.
Biotech developing peptide therapies for endocrine and metabolic disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug MBX 4291 enters first human safety trial Results expected Oct 2026 (estimated)
- New Once-Weekly shot shows promise for Long-Term hypoparathyroidism control Results expected May 2027 (estimated)
-
Weekly shot could free hypoparathyroidism patients from daily pills
Disease control Recruiting nowThis Phase 3 trial tests whether a once-weekly injection of canvuparatide (MBX 2109) can help adults with hypoparathyroidism reduce their daily calcium and vitamin D supplements while keeping blood calcium in a healthy range. The study includes 160 participants who will receive e…
Phase 3 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New obesity drug MBX 4291 enters first human safety trial
Disease control Recruiting nowThis early-stage study is testing an experimental drug, MBX 4291, in 124 adults with obesity. The main goal is to check the drug's safety and how the body processes it. Participants will receive either the drug or a placebo as a shot under the skin, and researchers will monitor f…
Phase 1 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC